Nishio S, et al. - In this phase 2 trial of irinotecan hydrochloride (CPT-11), researchers assessed its anti-tumor activity and toxicity in patients with advanced or recurrent endometrial cancer who were assigned to two pretreatment regimens. These patients received a 90-minute intravenous infusion of CPT-11 (100 mg/m²) on days 1, 8, and 15 of a 4-week cycle, aiming for an effect with ≤ 2 cycles. They assessed the response rate, progression-free survival, overall survival, and adverse events. They used RECIST version 1.1 and NCI-CTC AE version 3.0 to assess antitumor effect and adverse events, respectively. They found that, with controllable adverse events, CPT-11 as a single agent demonstrated anti-tumor activity for advanced or recurrent endometrial cancer.